MENLO PARK, Calif.--(BUSINESS WIRE)--CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), an innovative biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat diseases associated with aging, today announced that its Chief Executive Officer Simon Allen will present an overview of the company and its recent developments at the 2016 BIO Investor Forum in San Francisco. Mr. Allen will discuss CohBar’s recent announcements regarding the advancement of its preclinical candidates CB4209 and CB4211 into IND-enabling activities and the company’s discovery of new biologically active peptides in the mitochondrial genome.
|Date:||Wednesday, October 19, 2016|
|Location:||Westin St. Francis Hotel, San Francisco, CA|
A replay of the webcast will also be available on CohBar’s website at: www.cohbar.com following the conference.
The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and One-on-One PartneringTM meetings.
CohBar (OTCQX: CWBR and TSXV: COB.U) is a leader in the research and development of mitochondria-based therapeutics, an emerging class of drugs for the treatment of diseases associated with aging. MBTs originate from the discovery of a novel group of peptides within the genome of mitochondria, the powerhouses of the cell. This groundbreaking discovery was made by our founders, world leaders in the biology of aging, metabolism and mitochondrial genomics. MBTs offer the potential to address a broad range of diseases such as type 2 diabetes, obesity, NASH, cancer, atherosclerosis and neurodegenerative disorders.
For additional company information, please visit www.cohbar.com.